7 STRAITS VIEW, SINGAPORE, U0
Wave Life Sciences Reports Positive Phase 1 INLIGHT Data: Body Composition and Fat Reductions
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Investor Presentation
Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Positive Data from Wave Life Sciences' Phase 1 Trial of WVE-007 for Obesity
Corporate Presentation November 17, 2025
Reports Third Quarter 2025 Financial Results and Provides Business Update
FY 2024
Q3
Q2
Q1
Amended Annual Report
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Definitive Proxy Statement
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement